pharmaceuticals

US drug-policy shifts could cost Swiss pharma billions, study warns

An industry-backed study warns that changes to US pharmaceutical policy could cost Switzerland almost CHF95 billion by 2040. The scenarios include production moving to the United States and a new US approach to drug pricing, with potential consequences for Swiss growth and patients.